Clinical Trials Directory

Trials / Completed

CompletedNCT07465731

A Trial to Compare the Amount of Centanafadine That Enters the Bloodstream for Two Different Formulations of Centanafadine

A Phase 1, Randomized, Open-label, Parallel-arm Trial to Assess Relative Bioavailability of Centanafadine Sustained-Release (SR) Tablet to Once-Daily Extended-Release (QD XR) Capsule Following Oral Administration in Healthy Adult Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
62 (actual)
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

The purpose of this trial is to assess relative bioavailability of centanafadine (CTN) SR tablet to CTN QD XR capsule in healthy adult participants.

Conditions

Interventions

TypeNameDescription
DRUGCentanafadine SROral tablets.
DRUGCentanafadine QD XROral capsules.

Timeline

Start date
2022-10-27
Primary completion
2023-03-26
Completion
2023-03-26
First posted
2026-03-12
Last updated
2026-03-12

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT07465731. Inclusion in this directory is not an endorsement.

A Trial to Compare the Amount of Centanafadine That Enters the Bloodstream for Two Different Formulations of Centanafadi (NCT07465731) · Clinical Trials Directory